Learn more

VALPHARMA SA

Overview
  • Total Patents
    70
About

VALPHARMA SA has a total of 70 patent applications. Its first patent ever was published in 1995. It filed its patents most often in Italy, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, environmental technology and machines are SMITH HOWARD J & ASS PTY LTD, ARTURO JIMENEZ BAYARDO and TRANSAVE INC.

Patent filings per year

Chart showing VALPHARMA SAs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Valducci Roberto 58
#2 Alighieri Tiziano 47
#3 Avanessian Serozh 46
#4 Serozh Avanessian 5
#5 Roberto Valducci 5
#6 Raffaeli William 4
#7 Tiziano Alighieri 4
#8 Valducci Robert 3
#9 Avenessian Serozh 1
#10 Tiziano Alichierl 1

Latest patents

Publication Filing date Title
WO2010069951A1 Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins
EP2249812A1 Oral pharmaceutical formulations containing gliclazide
CN101854921A Pharmaceutical formulations for oral administration of PPI
EP2046305A2 Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
CN101472569A A pharmaceutical composition for the oral administration of omega polyenoic fatty acids
BRPI0616276A2 venlafaxine hydrochloride controlled release pharmaceutical composition and process for preparing it
EP1374867A1 Use of chloroquine, hydroxychloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards hiv sensitive strains and towards hiv strains which are resistant to both nucleosidic and non-nucleosidic reverse transcriptase inhibitors and to proteases inhibitors
EP1346723A1 Multiparticulate enteric coated and multiparticulate enteric coated prolonged release formulations containing NADH
JP2003048828A Modified release pharmaceutical composition containing bupropion hydrochloride as active substance
EP1395260A1 Use of the opioid antagonist naltrexone to prevent and control side effects caused by opioids
EP1228763A1 Multiparticulate formulations of lithium salts for once-a-day administration
IL122719D0 Controlled release pharmaceutical dosage forms for oral administration containing nifedipine as active substance and process for their preparation
US5871775A Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
EP0820703A1 Compositions for nutritional integration comprising prolonged-release hydrosoluble vitamins